0001104659-23-089331.txt : 20230809 0001104659-23-089331.hdr.sgml : 20230809 20230809163020 ACCESSION NUMBER: 0001104659-23-089331 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230807 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Jennifer Kayden CENTRAL INDEX KEY: 0001801372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 231155654 MAIL ADDRESS: STREET 1: C/O KRYSTAL BIOTECH, INC. STREET 2: 2100 WHARTON STREET, SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 FORMER NAME: FORMER CONFORMED NAME: Chien Jennifer DATE OF NAME CHANGE: 20200128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 4 1 tm2323302-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-08-07 0 0001649904 RHYTHM PHARMACEUTICALS, INC. RYTM 0001801372 Lee Jennifer Kayden 222 BERKELEY STREET, 12TH FLOOR BOSTON MA 02116 0 1 0 0 EVP, Head of North America 1 Common Stock 2023-08-07 4 M 0 8591 6.80 A 14517 D Common Stock 2023-08-07 4 S 0 11223 24.1778 D 3294 D Common Stock 2023-08-09 4 M 0 1718 6.80 A 5012 D Common Stock 2023-08-09 4 S 0 1718 24.66 D 3294 D Stock Option (Right to Buy) 6.80 2023-08-07 4 M 0 8591 0 D 2032-02-08 Common Stock 8591 73909 D Stock Option (Right to Buy) 6.80 2023-08-09 4 M 0 1718 0 D 2032-02-08 Common Stock 1718 72191 D Includes 986 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2023. The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. /s/ Hunter Smith, Attorney-in-Fact for Jennifer Lee 2023-08-09